# TNFα Monoclonal Antibody for Acute Spinal Cord Injury

> **NCT04988425** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shanghai Changzheng Hospital** · enrollment: 90 (estimated)

## Conditions studied

- Spinal Cord Injuries

## Interventions

- **DRUG:** TNFα Monoclonal Antibody
- **DRUG:** Methylprednisolone
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT04988425
- **Lead sponsor:** Shanghai Changzheng Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-01
- **Primary completion:** 2023-08-30
- **Final completion:** 2023-08-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2022-05-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04988425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04988425, "TNFα Monoclonal Antibody for Acute Spinal Cord Injury". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT04988425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*